301 results on '"Rattotti, Sara"'
Search Results
2. Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment
3. Local Radiotherapy and MRD-Driven Immunotherapy in Early-Stage Follicular Lymphoma: Final Results of the FIL - 'MIRO' Multicenter Phase II Trial
4. HCV infection and non-Hodgkin lymphomas: an evolving story
5. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection
6. A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi
7. Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study
8. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection
9. Assessing the Efficacy of Early Therapies against SARS-CoV-2 in Hematological Patients: A Real-Life Study from a COVID-19 Referral Centre in Northern Italy
10. Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi
11. Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi
12. Associated Cancers in Waldenström Macroglobulinemia: Clues for Common Genetic Predisposition
13. B‐cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non‐Hodgkin's Lymphoma
14. Microarray Demonstrates Different Gene Expression Profiling Signatures Between Waldenström Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance
15. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström's macroglobulinemia and related lymphoid neoplasms
16. Distinctive Clinical and Histological Features of Waldenström's Macroglobulinemia and Splenic Marginal Zone Lymphoma
17. Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus–Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi.
18. Prognostic impact of somatic mutations on time to first treatment: Results of targeted next‐generation sequencing in 211 patients with early stage chronic lymphocytic leukemia
19. Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma
20. Bone marrow assessment in asymptomatic immunoglobulin M monoclonal gammopathies
21. Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires
22. High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma
23. Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features
24. Systematic screening for SARS-CoV-2 in patients with hematological malignancies on active anticancer treatment in the outpatient setting
25. Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma
26. Mutational and immunogenetic landscape of HCV ‐associated B‐cell lymphoproliferative disorders
27. A brief rituximab, bendamustine, mitoxantrone (R‐BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL)
28. Direct‐acting antivirals in hepatitis C virus‐positive mantle cell lymphomas
29. Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases
30. Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study
31. Targeted next‐generation sequencing reveals molecular heterogeneity in non‐chronic lymphocytic leukemia clonal B‐cell lymphocytosis
32. “Miro” Study, a FIL multicenter phase II trial combining local radiotherapy and MRD-driven immunotherapy in early-stage follicular lymphoma.
33. Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis
34. Assessment of bone marrow involvement in non-Hodgkinʼs lymphomas: comparison between histology and flow cytometry
35. Mantle Cell Lymphoma of Mucosa‐Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study
36. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection
37. Waldenström Macroglobulinemia in Young Patients Treated in the Modern Era: A Multi-Institutional Italian Study
38. EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy
39. Whole Body Diffusion Weighted MRI (WB DWI) for the Management of Multiple Myeloma: High Concordance between MRI Diffuse Pattern and BONE Marrow Plasma CELL Infiltration RATE
40. Targeted Next Generation Sequencing Reveals Molecular Heterogeneity in Non-CLL Clonal B-Cell Lymphocytosis
41. MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL)
42. Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients
43. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkinʼs lymphomas
44. Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection
45. MYC Rearranged Aggressive B-Cell Lymphomas
46. Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue
47. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network
48. A risk‐stratification model based on the initial concentration of the serum monoclonal protein andMYD 88mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders
49. Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome
50. Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the Prospective International NF10 Study By Fondazione Italiana Linfomi
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.